Page 101 - Fertility in Women with Rheumatoid Arthritis Vruchtbaarheid van vrouwen met reumatoïde artritis

21. Tal R, Tal O, Seifer BJ, Seifer DB. Antimullerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil Steril. 2015 Jan;103(1):119-30 e3.
22. Rongieres C, Colella C, Lehert P. To what extent does Anti-Mullerian Hormone contribute to a better prediction of live birth after IVF? J Assist Reprod Genet. 2015 Jan;32(1):37-43.
23. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S, et al. Antimullerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol. 2011 Apr;117(4):798-804.
24. Hagen CP, Vestergaard S, Juul A, Skakkebaek NE, Andersson AM, Main KM, et al. Low concentration of circulating antimullerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril. 2012 Dec;98(6):1602-8 e2.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classi cation of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315-24.
26. de Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum. 2008 Sep 15;59(9):1241-8.
27. de Man YA, Hazes JM, van de Geijn FE, Krommenhoek C, Dolhain RJ. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum. 2007 Jun 15;57(5):716-22.
28. Welsh P, Smith K, Nelson SM. A single-centre evaluation of two new anti-Mullerian hormone assays and comparison with the current clinical standard assay. Hum Reprod. 2014 May;29(5):1035-41.
29. Su HI, Sammel MD, Homer MV, Bui K, Haunschild C, Stanczyk FZ. Comparability of antimullerian hormone levels among commercially available immunoassays. Fertil Steril. 2014 Jun;101(6):1766-72 e1.
30. Barr DB, Landsittel D, Nishioka M, Thomas K, Curwin B, Raymer J, et al. A survey of laboratory and statistical issues related to farmworker exposure studies. Environ Health Perspect. 2006 Jun;114(6):961-8.
31. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011 Feb 20;30(4):377-99.
32. Brouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ. Levels of serum anti-Mullerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Apr 1;65(9):1534-8.
33. Schram CA, Stephenson AL, Hannam TG, Tullis E. Cystic brosis (cf) and ovarian reserve: A cross-sectional study
examining serum anti-mullerian hormone (amh) in young women. J Cyst Fibros. 2015 May;14(3):398-402. 6
34. van Dorp W, van den Heuvel-Eibrink MM, de Vries AC, Pluijm SM, Visser JA, Pieters R, et al. Decreased serum anti-Mullerian hormone levels in girls with newly diagnosed cancer. Hum Reprod. 2014 Feb;29(2):337-42.
35. Senates E, Colak Y, Erdem ED, Yesil A, Coskunpinar E, Sahin O, et al. Serum anti-Mullerian hormone levels are lower in reproductive-age women with Crohn’s disease compared to healthy control women. J Crohns Colitis. 2012 Apr 1.
36. Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus. 2011 Oct;20(11):1193-7.
37. Isik S, Ozcan HN, Ozuguz U, Tutuncu YA, Berker D, Alimli AG, et al. Evaluation of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012 Jan;97(1):261-9.
38. Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum. 2009 Nov 15;61(11):1472-83.
39. Karri S, G V. Effect of methotrexate and leucovorin on female reproductive tract of albino rats. Cell Biochem Funct. 2011 Jan-Feb;29(1):1-21.
40. Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce JC. The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Hum Reprod. 2012 Jun;27(6):1829-39.
41. Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril. 2013 May;99(6):1644-53.
42. Andersen AN, Witjes H, Gordon K, Mannaerts B, Xpect i. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre- treatment. Hum Reprod. 2011 Dec;26(12):3413-23.
43. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016 Feb 17.
AMH in RA – time to pregnancy
99